Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5268044
Max Phase: Preclinical
Molecular Formula: C154H222BBrF4N36O20
Molecular Weight: 3064.41
Associated Items:
ID: ALA5268044
Max Phase: Preclinical
Molecular Formula: C154H222BBrF4N36O20
Molecular Weight: 3064.41
Associated Items:
Canonical SMILES: CC[C@@H](C)[C@@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCc1ccccc1)NC(=O)[C@H](NC(=O)[C@@H](CCCCN)NC(=O)[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CCCCN)NC(=O)[C@H](NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H](CC(C)C)NC(=O)CCc1cn(CCN2CCCc3cc(/C=C/C4=C(Br)C(/C=C/c5cc6c7c(c5)CCCN7CCC6)=[O+][B-](F)(C(F)(F)F)O4)ccc32)nn1)C1CCCCC1)[C@H](C)CC)C1CCCCC1)[C@H](C)CC)C(=O)N[C@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C154H222BBrF4N36O20/c1-9-94(6)128(146(211)184-119(69-60-98-39-18-13-19-40-98)137(202)179-116(53-31-77-173-151(166)167)139(204)188-130(96(8)11-3)147(212)186-121(90-100-57-66-111(197)67-58-100)143(208)177-112(134(163)199)68-59-97-37-16-12-17-38-97)187-138(203)114(51-27-29-75-162)183-149(214)132(105-44-22-15-23-45-105)191-141(206)118(55-33-79-175-153(170)171)181-145(210)129(95(7)10-2)189-144(209)122(91-102-56-64-103-41-24-25-46-106(103)87-102)185-136(201)115(52-30-76-172-150(164)165)178-135(200)113(50-26-28-74-161)182-148(213)131(104-42-20-14-21-43-104)190-140(205)117(54-32-78-174-152(168)169)180-142(207)120(85-93(4)5)176-126(198)73-65-110-92-196(193-192-110)84-83-194-80-34-47-107-86-99(61-70-123(107)194)62-71-124-127(156)125(216-155(160,215-124)154(157,158)159)72-63-101-88-108-48-35-81-195-82-36-49-109(89-101)133(108)195/h12-13,16-19,24-25,37-41,46,56-58,61-64,66-67,70-72,86-89,92-96,104-105,112-122,128-132,197H,9-11,14-15,20-23,26-36,42-45,47-55,59-60,65,68-69,73-85,90-91,161-162H2,1-8H3,(H2,163,199)(H,176,198)(H,177,208)(H,178,200)(H,179,202)(H,180,207)(H,181,210)(H,182,213)(H,183,214)(H,184,211)(H,185,201)(H,186,212)(H,187,203)(H,188,204)(H,189,209)(H,190,205)(H,191,206)(H4,164,165,172)(H4,166,167,173)(H4,168,169,174)(H4,170,171,175)/b71-62+,72-63+/t94-,95-,96-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,128-,129-,130-,131-,132-,155?/m1/s1
Standard InChI Key: TXGITVRMXSNYMY-WNXUKHPPSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 3064.41 | Molecular Weight (Monoisotopic): 3061.6674 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Okamoto H, Murano SA, Ikekawa K, Katsuyama M, Konno S, Taguchi A, Takayama K, Taniguchi A, Hayashi Y.. (2023) Inactivation of myostatin by photooxygenation using functionalized d-peptides., 14 (2.0): [PMID:36846372] [10.1039/d2md00425a] |
Source(1):